Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.

NCT04969627 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 analogue combined with metformin or metformin alone affects body weight and hormone levels in overweight or obese Chinese women with polycystic ovary syndrome (PCOS) and high androgen levels.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 60 people

Who can join Ages 18–40 · female only

Timeline Started 2021-01 · est. completion 2022-03

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04969627 ↗

Description as written by the study sponsor.

To study the effects of GLP-1 analogues combined with metformin and metformin on gonadal and metabolic profiles in PCOS patients with BMI ≥ 24 in China. 60 cases of overweight PCOS patients were collected from Shengjing hospital. The intervention period was 3 months after intervention with met or met + GLP-1. To evaluate the improvement of met or met + GLP-1 in the treatment of hyperandremia, glucose metabolism, BMI, waist circumference, menstruation, hairiness and acne in PCOS patients with different BMI.

Treatments tested

Metformin Drug

Use Metformin for 3 months to treat PCOS
Exenatide Drug

Use Exenatide for 3 months to treat PCOS

Main thing measured	Change in body weight
Sponsor	Bing He
Conditions studied	Polycystic Ovary Syndrome
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04969627 ↗